FDA-cleared profile

Neurophet AQUA

Neurophet., Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: Neurophet AQUA is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from a set of MR images; volumetric data may be compared to reference percentile data.

Clinical role
Automatic brain-structure and lesion labeling, visualization, volumetric quantification, and report support.
Images and patients
MRI · Brain; segmentable structures and lesions
Key limitation
Keep in mind: Results require trained-physician review and supported MRI protocols, image quality, structures, lesions, and reference data; public materials do not establish clinical outcome performance for every use.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Neurophet AQUA is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from a set of MR images; volumetric data may be compared to reference percentile data.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain; segmentable structures and lesions Input: Supported DICOM brain MRI studies, including specified 3D T1 and FLAIR sequences.
  • Who uses it?Intended users: Trained physicians and qualified neuroimaging professionals.
  • What does the software produce?Output: Segmented color overlays, brain-structure and lesion volumes, morphometric reports, percentile comparisons, and DICOM results.
  • What is its most important limitation?Key limitation: Results require trained-physician review and supported MRI protocols, image quality, structures, lesions, and reference data; public materials do not establish clinical outcome performance for every use.

Clinical takeaway. Clinical role: Neurophet AQUA is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from a set of MR images; volumetric data may be compared to reference percentile data.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports that no additional performance testing was conducted for this Special 510(k), because the modifications do not change the intended use or performance characteristics compared to the predicate. Design verification and validation confirmed the device meets the same performance specifications as the predicate, and the software was verified and validated. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Neurophet AQUA is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from a set of MR images; volumetric data may be compared to reference percentile data.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Automatic brain-structure and lesion labeling, visualization, volumetric quantification, and report support.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported DICOM brain MRI studies, including specified 3D T1 and FLAIR sequences.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Segmented color overlays, brain-structure and lesion volumes, morphometric reports, percentile comparisons, and DICOM results.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Clinical brain MRI workflows using supported acquisition protocols.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Trained physicians and qualified neuroimaging professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Results require trained-physician review and supported MRI protocols, image quality, structures, lesions, and reference data; public materials do not establish clinical outcome performance for every use.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports that no additional performance testing was conducted for this Special 510(k), because the modifications do not change the intended use or performance characteristics compared to the predicate. Design verification and validation confirmed the device meets the same performance specifications as the predicate, and the software was verified and validated. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "No additional performance testing was conducted for Neurophet AQUA, because the modifications implemented for this Special 510(k) do not change the intended use or performance characteristics of the device compared to the predicate device" … "through design verification and validation performed under the company’s design control procedures, that the subject device meets the same performance specifications as the predicate device". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports that no additional performance testing was conducted for this Special 510(k), because the modifications do not change the intended use or performance characteristics compared to the predicate. Design verification and validation confirmed the device meets the same performance specifications as the predicate, and the software was verified and validated. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "No additional performance testing was conducted for Neurophet AQUA, because the modifications implemented for this Special 510(k) do not change the intended use or performance characteristics of the device compared to the predicate device" … "through design verification and validation performed under the company’s design control procedures, that the subject device meets the same performance specifications as the predicate device". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K261273 FDA evidence package for Neurophet AQUA

  • DesignSpecial 510(k) non-clinical and software verification package for a modification with no additional performance testing because intended use and performance characteristics were unchanged from the predicate.
  • PopulationBrain; segmentable structures and lesions
  • Scopeexact submission
  • Tested versionNeurophet AQUA configuration described in K261273
  • IndependenceSponsor or vendor study

K261273

The FDA summary states that no additional performance testing was conducted for this Special 510(k); this does not establish independent clinical validation.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K261273 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported DICOM brain MRI studies, including specified 3D T1 and FLAIR sequences.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) K261273: Neurophet AQUA

  2. Routing

    Source context, not route validation: The FDA package describes specified 3D T1 and FLAIR MRI inputs in DICOM format, DICOM output for DICOM workstations and PACS, automated quality checks, and morphometric reports.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) K261273: Neurophet AQUA

  3. AI processing

    Source context, not route validation: The FDA package describes on-premise and off-premise cloud-based analysis on Windows and off-the-shelf hardware; current hosting responsibility, security, availability, and site configuration remain unverified.

    Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) K261273: Neurophet AQUA

  4. Returned objects

    Source context, not route validation: Segmented color overlays, brain-structure and lesion volumes, morphometric reports, percentile comparisons, and DICOM results.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) K261273: Neurophet AQUA

  5. Viewer/worklist/report

    Unresolved route: Segmented color overlays, brain-structure and lesion volumes, morphometric reports, percentile comparisons, and DICOM results.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) K261273: Neurophet AQUA

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes on-premise and off-premise cloud-based analysis on Windows and off-the-shelf hardware; current hosting responsibility, security, availability, and site configuration remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04

This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

Integration
The FDA package describes specified 3D T1 and FLAIR MRI inputs in DICOM format, DICOM output for DICOM workstations and PACS, automated quality checks, and morphometric reports.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Training
Only trained physicians and qualified neuroimaging professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K261273 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Results require trained-physician review and supported MRI protocols, image quality, structures, lesions, and reference data; public materials do not establish clinical outcome performance for every use.
  • Exact FDA submission
  • Checked 2026-09-04

This is buyer-facing monitoring guidance derived from the exact cleared or authorized scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K261273 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared or authorized release includes them.

Deployment boundary

The FDA package describes on-premise and off-premise cloud-based analysis on Windows and off-the-shelf hardware; current hosting responsibility, security, availability, and site configuration remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA package describes specified 3D T1 and FLAIR MRI inputs in DICOM format, DICOM output for DICOM workstations and PACS, automated quality checks, and morphometric reports.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Results require trained-physician review and supported MRI protocols, image quality, structures, lesions, and reference data; public materials do not establish clinical outcome performance for every use.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K261273 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Results require trained-physician review and supported MRI protocols, image quality, structures, lesions, and reference data; public materials do not establish clinical outcome performance for every use.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. brain MRI image-analysis software limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K261273
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Brain; segmentable structures and lesions
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-05-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
12Source classes checked
6Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Six PubMed records were screened. They evaluate or use Neurophet AQUA, but none states an AQUA software version linked to the K261273 configuration; all six records are quarantined and none is promoted. The current discovery snapshot contains 6 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision material, fda pma record, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) K261273: Neurophet AQUA

    U.S. Food and Drug Administration - Published 2026-05-15 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Neurophet AQUA model card (K261273)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, integration, anatomy, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K261273 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K254015

CoLumbo C-Spine

Smart Soft Healthcare AD

Authorized purpose: Post-process previously acquired cervical-spine MR images to segment vertebrae and disks, calculate quantitative measurements, label out-of-range values, and export results for user review and interpretation.

Modality
MRI
Anatomy
Cervical spine: vertebrae C3-C7 and disks C2C3 through C7T1
Decision
2026-04-01
FDA-cleared K253413

LiverMultiScan (v6.0)

Perspectum, Ltd.

Authorized purpose: LiverMultiScan v6.0 is MR diagnostic software for non-invasive liver-health assessment that generates, displays, and supports review of MR data and quantitative cT1, PDFF, and LIC metrics or composite images for trained healthcare-professional interpretation.

Modality
MRI
Anatomy
Liver
Decision
2026-03-09

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history